AstraZeneca, Janssen Pharma To Co-Market Prostate Drug In Japan
This article was originally published in PharmAsia News
AstraZeneca and Johnson & Johnson's Japan unit, Janssen Pharmaceuticals KK have agreed to collaborate on marketing Zytiga (abiraterone) already awaiting market approval.
You may also be interested in...
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.